vs
Side-by-side financial comparison of Cycurion, Inc. (CYCU) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $3.5M, roughly 1.5× Cycurion, Inc.). Cycurion, Inc. runs the higher net margin — -141.2% vs -507.8%, a 366.5% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -13.1%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -8.6%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
CYCU vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5M | $5.5M |
| Net Profit | $-5.0M | $-27.9M |
| Gross Margin | 12.1% | — |
| Operating Margin | -141.7% | -516.0% |
| Net Margin | -141.2% | -507.8% |
| Revenue YoY | -13.1% | 171.3% |
| Net Profit YoY | -546.8% | -48.3% |
| EPS (diluted) | $-11.09 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5M | $5.5M | ||
| Q3 25 | $3.8M | $0 | ||
| Q2 25 | $3.9M | $2.0M | ||
| Q1 25 | $3.9M | $2.3M | ||
| Q4 24 | $4.1M | $2.0M | ||
| Q3 24 | $4.5M | $1.8M | ||
| Q2 24 | $5.0M | $1.1M | ||
| Q1 24 | $4.2M | $3.4M |
| Q4 25 | $-5.0M | $-27.9M | ||
| Q3 25 | $-3.1M | $-32.7M | ||
| Q2 25 | $-5.3M | $-26.9M | ||
| Q1 25 | $-10.2M | $-21.5M | ||
| Q4 24 | $1.1M | $-18.8M | ||
| Q3 24 | $116.1K | $-25.5M | ||
| Q2 24 | $306.1K | $-20.9M | ||
| Q1 24 | $-312.5K | $-24.1M |
| Q4 25 | 12.1% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 17.5% | — | ||
| Q4 24 | 37.9% | — | ||
| Q3 24 | 16.1% | — | ||
| Q2 24 | 20.5% | — | ||
| Q1 24 | 8.2% | — |
| Q4 25 | -141.7% | -516.0% | ||
| Q3 25 | -118.2% | — | ||
| Q2 25 | -96.9% | -1347.1% | ||
| Q1 25 | -260.9% | -930.5% | ||
| Q4 24 | 31.9% | -985.8% | ||
| Q3 24 | 9.4% | -1448.4% | ||
| Q2 24 | 14.6% | -1915.4% | ||
| Q1 24 | -0.8% | -713.3% |
| Q4 25 | -141.2% | -507.8% | ||
| Q3 25 | -81.5% | — | ||
| Q2 25 | -136.1% | -1353.6% | ||
| Q1 25 | -264.8% | -935.2% | ||
| Q4 24 | 27.5% | -929.0% | ||
| Q3 24 | 2.6% | -1427.5% | ||
| Q2 24 | 6.1% | -1882.0% | ||
| Q1 24 | -7.4% | -705.4% |
| Q4 25 | $-11.09 | $-0.08 | ||
| Q3 25 | $-1.59 | $-0.09 | ||
| Q2 25 | $-0.15 | $-0.09 | ||
| Q1 25 | $-0.56 | $-0.08 | ||
| Q4 24 | $1.56 | $-0.07 | ||
| Q3 24 | $0.11 | $-0.10 | ||
| Q2 24 | $0.01 | $-0.09 | ||
| Q1 24 | $-0.02 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.1M | $246.9M |
| Total Assets | $33.5M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3M | $319.8M | ||
| Q3 25 | $3.7M | $297.3M | ||
| Q2 25 | $1.0M | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | $38.7K | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $20.1M | $246.9M | ||
| Q3 25 | $19.1M | $219.0M | ||
| Q2 25 | $14.0M | $248.7M | ||
| Q1 25 | $12.9M | $55.1M | ||
| Q4 24 | $3.5M | $71.5M | ||
| Q3 24 | $-3.7M | $88.8M | ||
| Q2 24 | $-3.4M | $108.9M | ||
| Q1 24 | $-2.8M | $53.8M |
| Q4 25 | $33.5M | $343.3M | ||
| Q3 25 | $32.3M | $316.6M | ||
| Q2 25 | $30.7M | $333.3M | ||
| Q1 25 | $31.5M | $138.4M | ||
| Q4 24 | $25.6M | $160.4M | ||
| Q3 24 | $2.9M | $180.2M | ||
| Q2 24 | $2.7M | $200.4M | ||
| Q1 24 | $3.1M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-26.7M |
| Free Cash FlowOCF − Capex | $-3.5M | — |
| FCF MarginFCF / Revenue | -98.8% | — |
| Capex IntensityCapex / Revenue | 5.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.3M | $-26.7M | ||
| Q3 25 | $-2.5M | $-24.2M | ||
| Q2 25 | $-3.6M | $-20.2M | ||
| Q1 25 | $-2.7M | $-22.0M | ||
| Q4 24 | $-205.7K | $-18.3M | ||
| Q3 24 | $-315.2K | $-21.6M | ||
| Q2 24 | $-578.0K | $-21.5M | ||
| Q1 24 | $-272.4K | $-19.8M |
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-2.6M | $-24.3M | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $-2.8M | — | ||
| Q4 24 | $-310.7K | $-18.3M | ||
| Q3 24 | $-420.2K | $-21.6M | ||
| Q2 24 | $-711.0K | $-21.7M | ||
| Q1 24 | $-377.4K | $-19.9M |
| Q4 25 | -98.8% | — | ||
| Q3 25 | -66.9% | — | ||
| Q2 25 | -94.2% | — | ||
| Q1 25 | -72.7% | — | ||
| Q4 24 | -7.6% | -905.5% | ||
| Q3 24 | -9.4% | -1210.9% | ||
| Q2 24 | -14.2% | -1951.9% | ||
| Q1 24 | -8.9% | -584.5% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.6% | 0.1% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 2.7% | 18.1% | ||
| Q1 24 | 2.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.18× | — | ||
| Q3 24 | -2.71× | — | ||
| Q2 24 | -1.89× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
